Vivos (RDGL) Other Non-Current Assets (2010 - 2025)

Vivos (RDGL) posted Other Non-Current Assets of $3000.0 for Q4 2025, up 348.43% sequentially from $669.0 in Q3 2018.

Vivos (RDGL) Other Non-Current Assets (2010 - 2025) Analysis & Trends

Vivos has reported Other Non-Current Assets for 10 years, with the latest figure at $3000.0 in Q4 2025.

Quarterly Other Non-Current Assets changed N/A year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3000.0 (changed N/A YoY) and the FY2025 annual result came in at $3000.0, changed N/A from the prior year.
Other Non-Current Assets grew to $3000.0 in Q4 2025 per RDGL's latest filing, from $669.0 in the prior quarter.
Over five years, Other Non-Current Assets peaked at $3000.0 in Q4 2025 and troughed at $3000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Abbott Laboratories	199.49 Bn	193.88 Bn	7.27 Bn	-
2	Stryker	127.80 Bn	124.32 Bn	4.50 Bn	3.23 Bn
3	Medtronic	118.98 Bn	109.76 Bn	6.41 Bn	4.15 Bn
4	Boston Scientific	73.58 Bn	73.04 Bn	3.85 Bn	45.22 Bn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn	616.40 Mn
6	Dexcom	34.34 Bn	32.39 Bn	830.00 Mn	273.70 Mn
7	GE HealthCare Technologies	33.76 Bn	31.66 Bn	2.18 Bn	2.25 Bn
8	Koninklijke Philips	26.37 Bn	23.05 Bn	4.55 Bn	148.78 Mn
9	Steris	23.07 Bn	22.59 Bn	684.20 Mn	215.10 Mn
10	Vivos	24.90 Mn	23.34 Mn	-3,105.00	113,703.00

Download Data